Tags

Type your tag names separated by a space and hit enter

Management of diabetic renal disease.

Abstract

Diabetic nephropathy is the leading cause of end stage renal failure (ESRF) worldwide, representing over 50% of patients on renal replacement therapy in some parts of the world. The condition is common in people with type 1 and type 2 diabetes, although the incidence appears to be declining, especially in type 1 diabetes. More than 1 in 3 people with type 2 diabetes have impaired kidney function. Advances in our understanding of the pathogenesis and natural history of the condition have enabled us to consider earlier therapy aimed at renal preservation and reduction in cardiovascular morbidity. Microalbuminuria is now established as the earliest risk marker for nephropathy in type 1 diabetes and cardiovascular disease in type 2 diabetes. This review examines the current concepts in the pathogenesis and management of diabetic nephropathy.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Diabetes and Metabolism, the Royal London Hospital, London, UK.

    Department of Diabetes and Metabolism, the Royal London Hospital, London, UK.

    Source

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26244141

    Citation

    Eboh, Cecil, and Tahseen A. Chowdhury. "Management of Diabetic Renal Disease." Annals of Translational Medicine, vol. 3, no. 11, 2015, p. 154.
    Eboh C, Chowdhury TA. Management of diabetic renal disease. Ann Transl Med. 2015;3(11):154.
    Eboh, C., & Chowdhury, T. A. (2015). Management of diabetic renal disease. Annals of Translational Medicine, 3(11), p. 154. doi:10.3978/j.issn.2305-5839.2015.06.25.
    Eboh C, Chowdhury TA. Management of Diabetic Renal Disease. Ann Transl Med. 2015;3(11):154. PubMed PMID: 26244141.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Management of diabetic renal disease. AU - Eboh,Cecil, AU - Chowdhury,Tahseen A, PY - 2015/06/25/received PY - 2015/06/26/accepted PY - 2015/8/6/entrez PY - 2015/8/6/pubmed PY - 2015/8/6/medline KW - Diabetic nephropathy KW - microalbuminuria KW - screening KW - treatment SP - 154 EP - 154 JF - Annals of translational medicine JO - Ann Transl Med VL - 3 IS - 11 N2 - Diabetic nephropathy is the leading cause of end stage renal failure (ESRF) worldwide, representing over 50% of patients on renal replacement therapy in some parts of the world. The condition is common in people with type 1 and type 2 diabetes, although the incidence appears to be declining, especially in type 1 diabetes. More than 1 in 3 people with type 2 diabetes have impaired kidney function. Advances in our understanding of the pathogenesis and natural history of the condition have enabled us to consider earlier therapy aimed at renal preservation and reduction in cardiovascular morbidity. Microalbuminuria is now established as the earliest risk marker for nephropathy in type 1 diabetes and cardiovascular disease in type 2 diabetes. This review examines the current concepts in the pathogenesis and management of diabetic nephropathy. SN - 2305-5839 UR - https://www.unboundmedicine.com/medline/citation/26244141/full_citation L2 - http://dx.doi.org/10.3978/j.issn.2305-5839.2015.06.25 DB - PRIME DP - Unbound Medicine ER -